C
삼성에피스홀딩스
0126Z0KOSPI48.5 / 100
Reference Date: 2026-10-23
Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Samsung Epis Holdings is a biotech investment holding company with two subsidiaries, Samsung Bioepis and Epis Nex Lab. Samsung Bioepis focuses on commercializing 11 biosimilar products, contributing 96.7% of 2025 revenue, and is expanding into ADC drug development. Epis Nex Lab, established in 2025, is focused on next-generation biotech platforms but has not yet generated revenue.
Number of Employees
18people
Average Salary
—
Score Calculation Basis
Detailed Financial Score
PER
95.11Industry Average 15.000.0Point
6.3x industry avg (risky)
PBR
1.38Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
—Industry Average 8.003.5Point
Debt Ratio
6.92Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
2.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (6%, downtrend)
Current 326,500Won52-week high 743,00052-week low 299,000
1-month return3.0Point
1m -0.91% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral풍문또는보도에대한해명(미확정)(자회사의 주요경영사항)2026-10-21
- Neutral결산실적공시예고(안내공시)2026-10-14
- Neutral최대주주등소유주식변동신고서2026-10-06
- Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (중증 호산구 천식 치료제 SB41(Fasenra 바이오시밀러) 및 유전성 재발열 증후군 치료제 SB44(Ilaris 바이오시밀러) 파트너십 계약 체결)2026-10-01
- Neutral[기재정정]기업지배구조보고서공시2026-09-28